Wilms tumor 1 expression in malignant gliomas and correlation of 1KTS isoforms with p53 status

Journal of Neurosurgery

Volumn 107, Issue 3, 2007, Pages 586-592

  Clark, Aaron J ^a   Dos Santos, Wagner G ^a   McCready, Jessica ^a   Chen, Mike Y ^a   Van Meter, Timothy E ^a   Ware, Joy L ^a   Wolber, Sharon B ^a   Fillmore, Helen ^a   Broaddus, William C ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glioblastoma multiforme; KTS isoform; Malignant glioma; p53; WT1

Indexed keywords

ISOPROTEIN; MESSENGER RNA; PROTEIN P53; RIBOSOME RNA; WT1 PROTEIN;

ADULT; AGED; ARTICLE; ASTROCYTE; CANCER CELL CULTURE; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING TEST; WILD TYPE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; FEMALE; GENES, P53; GLIOMA; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; WT1 PROTEINS;

EID: 34249091595     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/JNS-07/09/0586     Document Type: Article

References (41)

1. Acs G, Pasha T, Zhang PJ: WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 23:110-118, 2004
2. Armstrong JF, Pritchard-Jones K, Bickmore WA, Hastie ND, Bard JB: The expression of the Wilms' tumor gene, WT1, in the developing mammalian embryo. Mech Dev 40:85-97, 1993
3. Barker FG II, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, et al: EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51:410-418, 2001
4. Bogler O, Huang HJS, Kleihues P, Cavenee WK: The P53 gene and its role in human brain-tumors. Glia 15:308-327, 1995
5. Buckler AJ, Pelletier J, Haber DA, Glaser T, Housman DE: Isolation, characterization, and expression of the murine Wilms-tumor gene (WT1) during kidney development. Mol Cell Biol 11:1707-1712, 1991
6. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, et al: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms tumor locus. Cell 60:509-520, 1990
7. CBTRUS: Primary Brain Tumors in the United States, 1998-2002. Statistical Report. Chicago: Central Brain Tumor Registry of the United States, 2006 (http://cbtrus.org/reports//2005-2006/2006report.pdf) [Accessed 23 February 2007]
8. Dechsukhum C, Ware JL, Ferreira-Gonzalez A, Wilkinson DS, Garrett CT: Detection of a novel truncated WT1 transcript in human neoplasia. Mol Diagn 5:117-128, 2000
9. Dennis SL, Manji SSM, Carrington DP, Scarcella DL, Ashley DM, Smith PJ, et al: Expression and mutation analysis of the Wilms' tumor 1 gene in human neural tumors. Int J Cancer 97:713-715, 2002
10. Dupont J, Wang X, Marshall DS, Leitao M, Hedvat CV, Hummer A, et al: Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol Oncol 94:449-455, 2004
11. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE: Alternative splicing and genomic structure of the Wilms tumor gene-WT1. Proc Natl Acad Sci U S A 88:9618-9622, 1991
12. Hastie ND: Life, sex, and WT1 isoforms - three amino acids can make all the difference. Cell 106:391-394, 2001
13. Idelman G, Glaser T, Roberts CT Jr, Werner H: WT1-p53 interactions in insulin-like growth factor-I receptor gene regulation. J Biol Chem 278:3474-3482, 2003
14. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, et al: WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84:3071-3079, 1994
15. Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer, in MacLeod CM (ed): Evaluation of Chemotherapeutic Agents. New York: Columbia University Press, 1949, pp 191-205
16. Lamborn KR, Chang SM, Prados MD: Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-Oncol 6:227-235, 2004
17. Louis DN, Gusella JF: A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet 11:412-415, 1995
18. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
19. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DM, Cavenee WK, et al: Malignant glioma: genetics and biology of a grave matter. Genes Devel 15:1311-1333, 2001
20. Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA: The WT1 gene-product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Devel 9:2143-2156, 1995
21. Maheswaran S, Park S, Bernard A, Morris JF, Rauscher FJ III, Hill DE, et al: Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci U S A 90:5100-5104, 1993
22. Menke AL, van der Eb AJ, Jochemsen AG: The Wilms' tumor 1 gene: oncogene or tumor suppressor gene? Int Rev Cytol 181:151-212, 1998
23. Menssen HD, Bertelmann E, Bartelt S, Schmidt RA, Pecher G, Schramm K, et al: Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens. J Cancer Res Clin Oncol 126:226-232, 2000
24. Misra A, Chattopadhyay P, Dinda AK, Sarkar C, Mahapatra AK, Hasnain SE, et al: Extensive intra-tumor heterogeneity in primary human glial tumors as a result of locus non-specific genomic alterations. J Neurooncol 48:1-12, 2000
25. Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y, Tamaki H, et al: High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 8:1167-1171, 2002
26. Nakahara Y, Okamoto H, Mineta T, Tabuchi K: Expression of the Wilms' tumor gene product WT1 in glioblastomas and medulloblastomas. Brain Tumor Pathol 21:113-116, 2004
27. Ohminami H, Yasukawa M, Fujita S: HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95:286-293, 2000
28. Oji Y, Suzuki T, Nakano Y, Maruno M, Nakatsuka S, Jomgeow T, et al: Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors. Cancer Sci 95:822-827, 2004
29. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, et al: Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 101:13885-13890, 2004
30. Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K, et al: Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 164:1873-1880, 2000
31. Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, et al: Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346:420-427, 2002
32. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human-malignant gliomas without p53 mutations. Cancer Res 53:2736-2739, 1993
33. Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK, et al: Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65:4051-4058, 2005
34. Schumacher V, Schuhen S, Sonner S, Weirich A, Leuschner I, Harms D, et al: Two molecular subgroups of Wilms' tumors with or without WT1 mutations. Clin Cancer Res 9:2005-2014, 2003
35. Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, et al: Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40:51-55, 1998
36. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011-1018, 2002
37. Svedberg H, Chylicki K, Baldetorp B, Rauscher FJ III, Gullberg U: Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program. Oncogene 16:925-932, 1998
38. Thangnipon W, Mizoguchi M, Kukita Y, Inazuka M, Iwaki T, Fukui M, et al: Distinct pattern of PCR-SSCP analysis of p53 mutations in human astrocytomas. Cancer Lett 141:195-201, 1999
39. Vousden KH, Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer 2:594-604, 2002
40. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217-224, 1996
41. Zapata-Benavides P, Tuna M, Lopez-Berestein G, Tari AM: Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation. Biochem Biophys Res Commun 295:784-790, 2002